-->

Tag: CHECKMATE-76K

Home / Established Year

Nivolumab is approved by the FDA for adjuvant treatment of Stage IIB/C melanoma
, , , ,

Nivolumab is approved by the FDA for adjuvant treatment of Stage IIB/C melanoma

Nov 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years of age and older who had undergone complete..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy